GlassScriptPhysician profile
Magally Prosper
NPI 1316985872
$565.65
in general payments reported to CMS, 2019-2025
7 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $360 · 2020: $61.43 · 2021: $86.78 · 2022: $57.62.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $284.36 | 2019-2022 | |
| Pfizer INC. | $93.03 | 2019-2021 | |
| Sobi, INC | $54.17 | 2019 | |
| Merck Sharp & Dohme LLC | $47.54 | 2021 | |
| Sanofi Pasteur INC. | $42.37 | 2019 | |
| Phadia US INC. | $30.33 | 2019-2022 | |
| Cranial Technologies, INC | $13.85 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Magally Prosper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.